Business Wire

Biognosys Launches Spectronaut 16 and Presents Major Advances to its Proteomics Platforms at the ASMS 2022 Annual Conference

Share

Biognosys, a leading inventor and developer of mass spectrometry-based proteomics solutions, today announced the company is attending the American Society for Mass Spectrometry (ASMS) Annual Conference from June 5 to June 9in Minneapolis (Minnesota, USA) where the company will launch Spectronaut 16 and present major scientific and technological advances of its proprietary proteomics research services.

Biognosys will host 2 breakfast seminars introducing Spectronaut 16, 2 oral talks, 1 workshop panel, 5 scientific posters, and 1 poster collaboration. In addition, their team of scientific experts will be present at booth #306 to answer questions and demo software.

Collectively, this presence demonstrates Biognosys’ significant contributions to transforming life science and clinical research with next-generation proteomics, particularly for proteomics data analysis and drug and biomarker discovery.

“Our major contribution to the ASMS scientific program once again highlights our relentless commitment to innovation in mass spectrometry-based proteomics,” said Lukas Reiter, Ph.D., Chief Technology Officer of Biognosys. "With our Spectronaut 16 release, we continue to drive progress in DIA proteomics, and our TrueDiscovery and TrueTarget presentations demonstrate the utility of our research platforms for drug discovery and clinical trials.”

Spectronaut 16 provides the deepest proteome coverage available

At this year’s ASMS conference, Biognosys will commemorate the 10th anniversary of its flagship software, Spectronaut, with the launch of Spectronaut 16 in two breakfast seminars. The first seminar, “Spectronaut 16: Reaching New Depths in DIA Proteomics with AI”, takes place on June 6 with presentations from Oliver Bernhardt (Biognosys) and guest speaker Birgit Schilling (The Buck Institute). The second seminar, “Spectronaut: The Best Ally for Your Visionary Projects,” on June 8 features guest speakers Jesper V. Olsen (University of Copenhagen) and Yansheng Liu (Yale University School of Medicine).

Further, Biognosys will present three posters, demonstrating the significant improvements in Spectronaut 16 for direct searches on complex DIA data with reduced analysis time, deep-learning-based scoring in a dia-PASEF analysis pipeline, and score identifications with minimal computation time through the neural network DeepXIC that uses ion chromatograms to score for identifications.

Biofluid biomarker discovery in neurodegenerative and chronic autoimmune diseases with TrueDiscovery

Biofluids can often be collected less invasively and more frequently than tissue samples to provide an overview of what is happening in the organism. At ASMS, Biognosys will highlight the clinical utility of its proprietary proteomics platform TrueDiscovery™ for unbiased biomarker discovery in biofluids in two oral presentations on June 6. The first oral presentation explores proteomics data collected from CSF and plasma samples in a clinical study in collaboration with Johns Hopkins University, aimed at detecting actionable biomarkers for Alzheimer’s disease (AD). The study identified several proteomic biomarkers for healthy and pathological individuals, some of which were shared in both sample types. The second talk will show data from a clinical study in collaboration with Takeda on Systemic Lupus Erythematosus (SLE). Novel as well as previously reported biomarkers have been identified in plasma and could be used to stratify the disease state. Moreover, disease-specific biomarkers could be described to differentiate patients with renal involvement.

Drug target identification in oncology with TrueTarget

In a collaboration between Biognosys, AstraZeneca, and Pelago Bioscience, proteomics was used to identify and characterize the protein targets of a kinase inhibitor compound across the CDK family. At ASMS, Biognosys will present data demonstrating the performance of its proprietary TrueTarget platform to reveal the target and binding affinity of the drug and highlight complementarities with two other proteomics-based techniques. The presentation builds further on earlier data from this study, published in ACS Chemical Biology.

Visit biognosys.com/asms2022 for a complete overview of Biognosys’ presence at ASMS.

About Spectronaut®

Spectronaut is Biognosys’ flagship data analysis software for data-independent acquisition (DIA) mass spectrometry (MS) based proteomics.

The software employs advanced Search, Artificial Intelligence (AI), and Machine Learning (ML) algorithms to translate data into actionable insights for life science research. Spectronaut enables reproducible and precise quantification of thousands of proteins in a single experiment and provides multidimensional insights into protein expression, function, and structure across all major biological species and sample types. For more information, visit spectronaut.com.

About TrueDiscovery™

The Biognosys TrueDiscovery platform offers integrated proteomics solutions across the entire drug development pipeline.

TrueDiscovery is powered by Hyper Reaction Monitoring (HRM) mass spectrometry, an advanced patented Data Independent Acquisition (DIA)-based protein quantification technology co-invented by tech pioneers at Biognosys.

TrueDiscovery is the only platform that searches the complete proteome to quantify thousands of the most relevant proteins, including an unlimited number of proteoforms. The platform enables the deepest unbiased profiling of tissue and biofluids proteomes with unbeatable specificity on a large scale. The generated data are highly reproducible and easily transferrable to clinical assays. Studies can be performed in a GLP certified and GCP compliant environment. For more information, visit truediscovery.bio.

About TrueTarget™

The Biognosys TrueTarget proteomics platform uniquely addresses the most pressing challenges in early drug discovery by identifying on- and off-targets to accelerate and de-risk drug development throughout the pipeline.

TrueTarget is powered by Limited Proteolysis Mass Spectrometry (LiP-MS), a proprietary, patented chemoproteomics technology co-developed by Biognosys. TrueTarget is the only tool to probe structural changes across the complete proteome with peptide-level resolution, providing unique insights into compound binding and target identification.

The platform enables elucidating mechanisms of action and revealing unanticipated toxicities. For more information, visit truetarget.bio.

About Biognosys

At Biognosys, we believe that deep proteome insights hold the key to breakthrough discoveries that can dramatically improve human health. We enable life science researchers and drug hunters to look at the proteome from every angle with our versatile portfolio of proprietary next-generation proteomics services, software, and kits, including the TrueDiscovery™, TrueTarget™, and TrueSignature™ platforms and flagship software Spectronaut®. These solutions provide a multi-dimensional view of protein expression, function, and structure in all biological species and sample types. Biognosys’ unique, patented technologies utilize high-resolution mass spectrometry to quantify thousands of proteins across thousands of samples with industry-leading precision, depth, and throughput. Through advanced data analytics, Biognosys translates data into actionable insights for R&D and clinical research. For more information, visit biognosys.com.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Yves Serroen
Head of Marketing and Communications
Phone +41 (0) 79 571 09 21
yves.serroen@biognosys.com

About Business Wire

Business Wire
Business Wire



Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Teva Announces Promising Interim Results From Its Study PEARL, About the Impact of AJOVY ® (fremanezumab)24.6.2022 18:54:00 CEST | Press release

Teva Pharmaceuticals Europe B.V. today announces promising interim results from its Pan-European Real World study (PEARL), presented for the first time at the European Academy of Neurology (EAN) Congress in Vienna, Austria. The two-year Pan-European Real World (PEARL) prospective, observational study of AJOVY® (fremanezumab), looks at its effectiveness in patients with chronic migraine or episodic migraine, and is an ongoing study sponsored by Teva Pharmaceuticals Europe BV.1 These findings further offer insight into the treatment of migraine in real-world clinical practice. The interim findings were presented by Faisal Mohammad Amin, Associate Professor of Neurology at the University of Copenhagen, Denmark. Out of the total planned 1100 patients in PEARL, 389 patients are included in the interim analysis presented. These findings show that 54.7% of patients in the study had their monthly-migraine-days reduced by 50% or more, over the six-month period from the start of treatment. Addit

Brigade-M3 European Acquisition Corp. 2021 Annual Report24.6.2022 16:59:00 CEST | Press release

Brigade-M3 European Acquisition Corp. (the “Company”), a special purpose acquisition company that was incorporated on 21 April 2021 under the laws of the Cayman Islands as an exempted company with limited liability and is listed on Euronext Amsterdam, today published its annual report for the period 21 April 2021 to 31 December 2021. The full report can be downloaded from the Company’s website via the following link: https://www.brigadem3eac.com/documents IMPORTANT INFORMATION This press release contains information that qualifies as inside information within the meaning of Article 7(1) of the EU Market Abuse Regulation. DISCLAIMER This announcement is not for distribution or release, directly or indirectly, and should not be distributed in or sent into, the United States, Australia, Canada, Japan, the Cayman Islands or South Africa or any other jurisdiction in which such distribution or release would be unlawful or would require registration or other measures. This announcement does n

PUMA Kicks Off Its Largest Web3 Collaboration To Date, with 10KTF Shop24.6.2022 16:41:00 CEST | Press release

PUMA has entered New Tokyo, the virtual city 10KTF calls home. The shop is known for its streetwear offerings and is owned by Wagmi-san, a digital artisan whose collections and NFT community recently welcomed the global sports brand. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220624005314/en/ PUMA Kicks Off Its Largest Web3 Collaboration To Date, with 10KTF Shop PUMA has entered New Tokyo, the virtual city 10KTF calls home. The shop is known for its streetwear offerings and is owned by Wagmi-san, a digital artisan whose collections and NFT community recently welcomed the global sports brand. (Photo: Business Wire) News of the partnership was shared at an event hosted by 10KTF last night in New York. Their event was one of many hosted during the week of NFT.NYC, a conference attended by crypto industry professionals, traders, and other web3 enthusiasts. The official announcement confirms weeks of speculation after PUMA tw

Suzano outlines ESG milestone achievements and commitments at second annual ESG call24.6.2022 16:14:00 CEST | Press release

Suzano, the world’s largest hardwood pulp producer, today held its second annual ESG Call centered around its ambition to be a ‘regenerative company for a regenerative society’. Today’s ESG Call spotlighted measurable progress and ambitions across three core areas of action: climate change, biodiversity and social development. On Climate Change, the ACT initiative of the French Government and CDP scored Suzano ahead of its pulp and paper industry peers in virtually every metric. In 2021, Suzano brought forward its target for removing 40 million tons of carbon dioxide from the atmosphere from 2030 to 2025 which is being achieved through improvements to its industrial processes, such as systematically replacing the use of fossil fuels at its industrial plants with biomass, and through conversion of degraded land. As part of the company’s social commitments, Suzano launched a target in 2020 to lift 200,000 people out of poverty. This is more than pertinent, given that in Brazil, 10% of th

Kyowa Kirin Receives Positive CHMP Opinion for Use of CRYSVITA ® ▼ (burosumab) for the Treatment of Tumour-Induced Osteomalacia (TIO)24.6.2022 15:38:00 CEST | Press release

Kyowa Kirin Co., Ltd. (TSE: 4151, Kyowa Kirin) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended that CRYSVITA® (burosumab) be approved for the treatment of FGF23-related hypophosphataemia in Tumour-Induced Osteomalacia (TIO) associated with phosphaturic mesenchymal tumours (PMTs) that cannot be curatively resected or localised in children and adolescents aged 1 to 17 years and in adults.1 CRYSVITA is also already licensed for use in the rare disease X-Linked Hypophosphataemia (XLH), for children and adolescents between 1 and 17 years of age with radiographic evidence of bone disease, and in adults.2 Also known as oncogenic osteomalacia, TIO is an acquired disorder caused by typically small, slow-growing, benign PMTs.3,4 It is a rare condition with less than 1000 cases reported in the medical literature,4 which mainly affects adults and with a mean onset age of 40 – 45 years.3,5 TIO is associated with p

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom